Data presented by UCLA researcher Dr. Pinchas Cohen at the Pediatric Academic Societies' 2005 annual meeting in Washington, D.C., demonstrated that non-growth hormone deficient primary insulin-like ...
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin ...
Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin) injection), the only recombinant human insulin-like growth factor-1 (rhIGF-1) ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mecasermin, when administered at the highest end of the ...
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to Bolster Eton’s Commercial Pediatric Endocrinology ...
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolio Product is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results